In both MLL-AF9 and Meis1a/Hoxa9 leukemic models, recipients of Zeb1-KO LSCs succumbed to AML with enhanced rapidity compared with recipients receiving control LSCs, indicating that Zeb1 deletion accelerates LSC-mediated disease progression (Figure 8, F and G). This evidence concerns the gene MLLT3 and acute myeloid leukemia.